Abstract
The aim of this piece is to provide estimates of the infection fatality rate (IFR) of COVID-19 in Mumbai during 2020, namely the fraction of SARS-CoV-2 infections which resulted in death. Estimates are presented for slums and nonslum areas, and for the city as a whole. These are based largely on the city’s official COVID-19 fatality data, seroprevalence data, and all-cause mortality data. Using recorded COVID-19 fatalities in the numerator, we obtain IFR estimates of 0.13%-0.17%. On the other hand, using excess deaths we obtain IFR estimates of 0.28%-0.40%. The estimates based on excess deaths are broadly consistent with the city’s age structure, and meta-analyses of COVID-19 age-stratified IFR. If excess deaths were largely from COVID-19, then only around half of COVID-19 deaths were officially recorded in the city. The analysis indicates that levels of excess mortality in excess deaths per 1000 population were similar in the city’s slums and nonslum areas. On the other hand the estimated ratio of excess deaths to official COVID-19 deaths in the slums was much higher than in nonslum areas, suggesting much weaker COVID-19 death reporting from the slums.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
N/A
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
There are no relevant ethical questions requiring approval
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
The manuscript has been updated to use monthly all-cause mortality data. This gives a clearer picture of mortality associated with the slums and nonslum areas of the city.
Data Availability
All data referred to in the manuscript is available publicly
